For the quarter ending 2026-03-31, DFTX had $4,681K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 |
|---|---|---|
| Research And Development | 41,484 | 117,665 |
| General And Administrative | 17,736 | 48,644 |
| Loss from operations | -59,220 | -166,309 |
| Total other income/(expense), net | -17,878 | -17,484 |
| Net loss | -77,098 | -183,793 |
| Stock-based compensation | 7,132 | 20,096 |
| Change in fair value on directors' deferred share units ('ddsu') | -1,030 | -1,460 |
| Amortization of intangible assets | - | 0 |
| Change in fair value of 2022 usd financing warrants | 20,046 | 22,831 |
| Gain on extinguishment of contribution payable | - | 0 |
| Amortization of discounts and premiums on investments, net | -591 | 1,821 |
| Unrealized foreign exchange | - | 0 |
| Other non-cash adjustments | 220 | 230 |
| Prepaid and other current assets | -585 | -152 |
| Other noncurrent assets | -118 | -30 |
| Accounts payable | 1,780 | 3,337 |
| Accrued expenses | 2,994 | 5,958 |
| Other liabilities, long-term | 29 | 40 |
| Net cash used in operating activities | -42,631 | -131,560 |
| Purchases of investments | 0 | 268,356 |
| Maturity of investments | 42,000 | 116,750 |
| Net cash provided by (used in) investing activities | 42,000 | -151,606 |
| Proceeds from equity offerings | - | 258,858 |
| Payment of equity offering costs | - | 15,946 |
| Proceeds from credit facility | - | 42,000 |
| Repayment of credit facility | - | 22,000 |
| Payment of credit facility issuance costs | - | 447 |
| Proceeds from the 2022 atm net of issuance costs | - | 0 |
| Payment of deferred financing fees related to 2024 atm | - | 0 |
| Proceeds from exercise of pre-funded warrants | 4 | - |
| Proceeds from exercise of 2022 usd financing warrants | 3,833 | 3,767 |
| Proceeds from exercise of options | 1,196 | 625 |
| Proceeds from issuance of common shares under espp | 276 | 412 |
| Withholding taxes paid on vested rsus | - | 0 |
| Net cash provided by financing activities | 5,309 | 267,269 |
| Effect of exchange rate changes on cash | 3 | -7 |
| Net increase/(decrease) in cash and cash equivalents | 4,681 | -15,904 |
| Cash and cash equivalents, beginning of period | 257,837 | 273,741 |
| Cash and cash equivalents, end of period | 262,518 | 257,837 |
Definium Therapeutics, Inc. (DFTX)
Definium Therapeutics, Inc. (DFTX)